These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients. Reischig T; Opatrný K; Treska V; Mares J; Jindra P; Svecová M Kidney Blood Press Res; 2005; 28(4):218-25. PubMed ID: 16043964 [TBL] [Abstract][Full Text] [Related]
23. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Hodson EM; Craig JC; Strippoli GF; Webster AC Cochrane Database Syst Rev; 2008 Apr; (2):CD003774. PubMed ID: 18425894 [TBL] [Abstract][Full Text] [Related]
24. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients. Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146 [TBL] [Abstract][Full Text] [Related]
29. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408 [TBL] [Abstract][Full Text] [Related]
30. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report. Ciszek M; Mucha K; Foroncewicz B; Chmura A; Pączek L Ann Transplant; 2014 Jan; 19():60-3. PubMed ID: 24481271 [TBL] [Abstract][Full Text] [Related]
31. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation]. Fricke L; Steinhoff J; Hartwig-Weber I; Bein G Dtsch Med Wochenschr; 1997 May; 122(18):565-71. PubMed ID: 9190308 [TBL] [Abstract][Full Text] [Related]
32. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Ahsan N; Holman MJ; Yang HC Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699 [TBL] [Abstract][Full Text] [Related]
33. Eradication of cytomegalovirus reactivation disease using high-dose acyclovir and targeted intravenous ganciclovir in kidney and kidney/pancreas transplantation. Shen GK; Alfrey EJ; Knoppel CL; Dafoe DC; Scandling JD Transplantation; 1997 Sep; 64(6):931-3. PubMed ID: 9326425 [TBL] [Abstract][Full Text] [Related]
34. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients. Axelrod D; Leventhal JR; Gallon LG; Parker MA; Kaufman DB Am J Transplant; 2005 Jun; 5(6):1423-9. PubMed ID: 15888050 [TBL] [Abstract][Full Text] [Related]
35. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790 [TBL] [Abstract][Full Text] [Related]
36. The impact of pretransplant cytomegalovirus infection on acute renal allograft rejection. Chen JH; Mao YY; He Q; Wu JY; Lv R Transplant Proc; 2005 Dec; 37(10):4203-7. PubMed ID: 16387078 [TBL] [Abstract][Full Text] [Related]
37. Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients. Yango A; Morrissey P; Zanabli A; Beaulieu J; Shemin D; Dworkin L; Monaco A; Gohh R Nephrol Dial Transplant; 2003 Apr; 18(4):809-13. PubMed ID: 12637653 [TBL] [Abstract][Full Text] [Related]
38. Epidemiology of cytomegalovirus infection after pancreas transplantation. Parsaik AK; Bhalla T; Dong M; Rostambeigi N; Dierkhising RA; Dean P; Abraham R; Prieto M; Kremers WK; Razonable RR; Kudva YC Transplantation; 2011 Nov; 92(9):1044-50. PubMed ID: 21904269 [TBL] [Abstract][Full Text] [Related]
39. Treatment of cytomegalovirus infection after renal transplantation: experience from a single center in China. Li Y; Yan H; Xue WJ; Tian PX; Ding XM; Pan XM; Feng XS; Xiang HL; Hou J; Tian XH; Zheng J; Ding CG; Fan P; Liu HB Ann Transplant; 2013 Mar; 18():125-35. PubMed ID: 23792512 [TBL] [Abstract][Full Text] [Related]
40. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M; Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]